Invobenitug (Procizumab) for critical heart conditions
Part of Heart & circulation clinical trials.
This trial tests a new drug, Invobenitug, for patients in shock caused by heart attack, infection, or sudden worsening of heart failure. It aims to see if the drug can help stabilize blood pressure and improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be in cardiogenic shock (blood pressure low despite medication, and lactate level high).
- Your shock must be due to a heart attack, severe infection, or acute heart failure.
- You must be between 18 and 80 years old.
- You cannot have been on blood pressure support drugs for more than 16 hours before starting the study drug.
- You cannot have been in the intensive care unit for more than 24 hours when you are randomly assigned to a treatment group.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies whether an inotrope medicine (a drug that helps the heart pump) works better than a placebo in adults in intensive care with cardiogenic shock. It may help doctors find safer, more effective treatment for this life-threatening condition.
This trial tests if unloading the heart during ECMO support helps patients recover better from cardiogenic shock. It compares different ways to reduce the heart's workload.
This trial studies whether putting in a small heart pump early (through the leg) helps people with a heart attack complicated by severe heart weakness (“cardiogenic shock”) compared with standard treatment. It aims to improve survival and recovery by supporting blood flow sooner.
This trial studies whether doctors can safely reduce heart and blood-pressure support sooner in people with severe heart failure “shock.” It may help avoid side effects of strong medicines/devices while keeping the body’s organs well supported.
This study tracks how well people with cardiogenic shock (a life-threatening drop in blood flow after a heart attack or heart failure worsening) do when treated with modern support devices and medicines.
This trial tests a new device called the VentriCure that helps the heart pump blood. It is for people with severe coronary artery disease and a weak heart who cannot have bypass surgery or choose not to.
Hear when a new Shock, Cardiogenic trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.